A VirusOFF interview with Nadia Yanhol on access to PrEP, mobile services, the role of communities and lessons from Ukraine for Eastern Europe and Central Asia.
In Ukraine, different forms of HIV pre-exposure prophylaxis are available free of charge. But what does this choice mean to someone who lives far from a healthcare facility, has been forced to relocate or fears being judged? Is access to a medicine enough when transport, support and trust are missing?
As part of the VirusOFF media campaign “From Rio to Geneva: HIV Prevention Choice, Access and Mobility in Practice”, implemented with the support of the IAS in the context of Rethink. Rebuild. Rise., we continue exploring practical lessons from AIDS 2026 for Eastern Europe and Central Asia. We speak with Nadia Yanhol, public health expert and HIV pre-exposure prophylaxis (PrEP) programme coordinator at the Alliance for Public Health (Ukraine), about how HIV prevention programmes operate amid Russia’s full-scale war. Our conversation is about choice measured not only by medicine availability but also by whether people can reach services; about mobile clinics that go where people are; about the essential role of community organizations; and about what Ukraine can bring to IAS 2027 in Geneva.
Nadia, you attended AIDS 2026 in Rio, and this was not your first international HIV conference. What does genuine choice in HIV prevention mean for Ukraine and our region today?
Speaking from my own experience and Ukraine’s experience, particularly in how we present access to PrEP, programmes are increasingly moving beyond HIV prevention alone towards a broader approach to maintaining health. For me, genuine choice means that people can influence how they protect their own health.
Some people prefer oral PrEP, which they can take themselves; others find an injectable option more convenient. But choice of product must go hand in hand with choice of an accessible place to receive services. And even when life circumstances change, access must continue.
Ukraine already has a concrete basis for such choice. In 2025, long-acting injectable cabotegravir was added to oral PrEP. Both options are provided free of charge and are available in every region of Ukraine. This marks an important transition from the initial pilot in 2025 to a wider network across the country.
Yet the availability of a medicine in a region says little about how easily an individual can obtain it. I suggest assessing genuine choice through simple questions: Does the person know which prevention option is available to them? Can they seek help without fear? How much time and money does travel require? Will the medicine be available at their next visit? Internal displacement and migration have added further challenges. If even one of these conditions is not met, choice remains limited.
In other words, the availability of a medicine does not necessarily mean access to it. At the same time, Ukraine now offers two forms of PrEP, and that is important experience for Eastern Europe and Central Asia.
You mentioned access. Who finds it hardest to obtain HIV prevention services today, and which barriers remain decisive?
I would not single out just one group, because each faces barriers of its own to some degree. How difficult access is depends on a person’s social circumstances, where they live, the security situation and their previous experience of the healthcare system.
It is usually harder for someone approaching services for the first time to find their way around. People who have used prevention, harm reduction or PrEP programmes for years already know the system better. For example, when someone moves from a large city to a small town, they may fear disclosure of personal information. If the necessary services are not available nearby, they have to travel to a larger city.
People who use drugs may have experienced judgement and may struggle to access different services together. For sex workers, flexible opening hours are important, and healthcare facilities cannot always provide them. That is why combining the work of public institutions and non-governmental organizations makes it possible to build a more comprehensive prevention system, including for access to PrEP.
For most key populations, I would identify three common requirements: safety, the physical ability to reach services and continuity of access. Providing a medicine free of charge does not, in itself, guarantee access. This is especially true now, when funding is being cut and support services are often among the first to be affected. We need to assess the full range of barriers and the entire package of services.
Young people and transgender people require particular attention: programmes need to be tailored to their needs. Ukraine also has new priority populations, including military personnel and veterans. HIV, hepatitis and tuberculosis are relevant issues for them too, so the Alliance for Public Health and partner organizations are extending their programmes to these groups. These are new challenges that need to be taken into account.
What role do non-governmental organizations and communities play today, especially amid the war and funding cuts?
HIV prevention and harm reduction services in Ukraine and many other countries have largely developed through communities and non-governmental organizations. That is because access begins with trust. Someone may avoid a healthcare facility for fear of being judged, but they need to be able to talk about their situation with someone they trust.
This is what helps turn information into an actual service. Time, trust, logistics and the ability to receive support where it is needed all matter, including in places where the healthcare system has very little presence.
Mobile clinics supported by the Alliance for Public Health are a good example. They have adapted their work to the needs of displaced people: they deliver prevention supplies and provide medical care, with doctors involved in their work.
This is a clear example of how services can move closer to people during a crisis. They do not stop; on the contrary, they follow people, wherever they are and whether or not they can travel to a healthcare facility themselves. For non-governmental organizations, this also means risks and considerable responsibility. But it explains why it is so important to fund communities and support continuity of services.
Many organizations employ people who themselves belong to key populations. That means communication people understand, direct contact and far fewer barriers. This can help establish prevention support quickly and then link the pathway that has been built to the healthcare system.
And I want to emphasize funding once again. You cannot fund only the medicine and forget the entire service pathway. The medicine may be available, but the person may never reach it. Testing, navigation, case management, access to information and ongoing support are all essential elements of prevention. Without them, the value of the medicine itself is lost for the person who needs it.
Which aspects of Ukraine’s HIV prevention experience during the war could be useful to other countries in Eastern Europe and Central Asia?
Ukraine did not stop delivering services during the war and even improved results on certain indicators. When the state could not continue financing some programmes at the beginning of the crisis, international donors stepped in. Ukraine has developed practical tools that could serve as examples and methodologies for other countries facing crises. This represents a tremendous amount of work and a real achievement.
The first lesson is service mobility. Vehicles can be adapted to make them more convenient for clients. Whereas certain Alliance programmes previously focused mainly on prevention, mobile clinics now combine prevention and medical services. They bring several models together in one place.
A mobile clinic provides access to prevention, treatment, information and a range of social services, including humanitarian assistance and food. Some clinics have dental facilities, which makes it possible to expand the range of support. This model brings care directly to individuals. It already has established operating procedures, organization and financing, and can be used during crises.
The second area is innovation. Ukraine is making considerable efforts to advocate for access to the newest medicines. Long-acting injectable PrEP is an example: cabotegravir is already in use, and we are awaiting the introduction of lenacapavir. Despite the war, efforts to expand access to innovation have not stopped.
There are digital tools too. For example, a virtual social worker (www.twiin.org.ua) has been developed so that people can get answers to their questions without leaving home. It is designed as an interactive consultation based on a peer-to-peer approach. Information can also be found online, but the opportunity for dialogue helps people feel supported rather than left alone with a problem. This is especially important during crises, when familiar routes to services are disrupted.
Logistics are also improving: people can receive medicines for longer periods and obtain care in another region without being tied to their place of registration. Despite the war, Ukraine remains among the countries actively developing innovations and prevention programmes. It is important to systematically document good practices. Given today’s crises, every country should have a practical guide for responding to emergencies. Ukraine has valuable experience to share: we present these approaches at international forums and share practical lessons with other countries.
Looking ahead to IAS 2027 in Geneva, what is the main message Ukraine and the region should bring to the global community?
I would put it this way: modern prevention methods must be accessible to people whose lives are shaped by crisis, war, displacement, stigma and unstable incomes. The experience of Ukraine and the region can help formulate concrete demands that need to be discussed and supported.
First, we need affordable and predictable supplies of medicines, including new options, and simpler registration procedures. In some countries, these processes take too long or are blocked altogether.
Second, funding must cover not only medicines but the whole service: testing, community work, navigation and support. This is absolutely essential.
Looking at the global situation, I would also advocate for greater involvement of Ukraine and people living through crises in research, programme implementation and quality assessment. We need to understand how these solutions work, what impact they have and how they can be adapted and scaled up.
Innovation is important and necessary today. But it should be judged by how far it expands access for people facing the greatest barriers. Because innovation itself, like a medicine alone, is not the goal. A comprehensive approach is needed.